Thrombosis and Inflammation in Acute Coronary Syndromes

Indexed in: EBSCO

Despite remarkable progress in fighting against myocardial infarction, the thrombotic complications of the coronary artery are still a significant cause of morbidity and mortality worldwide. ...
[view complete introduction]

US $
15

*(Excluding Mailing and Handling)



Antiplatelet Resistance

Pp. 79-103 (25)

Dilek Ural, İrem Yılmaz and Kurtuluş Karaüzüm

Abstract

Antiplatelet therapy is the keystone in secondary prevention of the patients with cardiovascular diseases. The efficacy of aspirin, clopidogrel and novel oral antiplatelets like prasugrel and ticagrelor in atherotrombotic events has been shown in several landmark clinical trials and meta-analyses. Nevertheless, a significant number of patients experience recurrent events despite antiplatelet therapy. Increasing evidence indicates that there is considerable variability in response to antiplatelet therapy among patients and those who have higher levels of platelet reactivity are at increased risk for recurrent ischaemic events. These findings raised the possibility that decreased response, or ‘resistance’ to oral antiplatelet drugs may underlie many subsequent major cardiovascular events (MACE). The main problem with ‘resistance’ is the lack of a clear definition. In this chapter, aspirin, clopidogrel and glycoprotein IIb/IIIa receptor inhibitor resistance in patients with acute coronary syndromes will be discussed by the concept of residual platelet activity.

Keywords:

Antiplatelet, antiplatelet resistance, aspirin, clopidogrel, aspirin resistance, clopidogrel resistance, acute coronary syndrome, platelet function assays.

Affiliation:

Kocaeli University, School of Medicine, Department of Cardiology Umuttepe Kampüsü - 41380 Kocaeli/Türkiye.